Last reviewed · How we verify
ACs
ACs are anticholinergic agents that block acetylcholine receptors to reduce parasympathetic nervous system activity.
ACs are anticholinergic agents that block acetylcholine receptors to reduce parasympathetic nervous system activity. Used for Chronic obstructive pulmonary disease (COPD), Asthma, Gastrointestinal disorders (antispasmodic use).
At a glance
| Generic name | ACs |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Anticholinergic agent |
| Target | Muscarinic acetylcholine receptors (non-selective or subtype-specific) |
| Modality | Small molecule |
| Therapeutic area | Multiple (Respiratory, Gastrointestinal, Ophthalmology, Neurology) |
| Phase | FDA-approved |
Mechanism of action
Anticholinergics competitively inhibit acetylcholine binding at muscarinic or nicotinic receptors, reducing cholinergic signaling. This leads to decreased secretions, reduced smooth muscle contractions, and other parasympathomimetic effects depending on the specific receptor subtype and tissue targeted.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
- Gastrointestinal disorders (antispasmodic use)
- Parkinson's disease (tremor management)
Common side effects
- Dry mouth
- Urinary retention
- Constipation
- Blurred vision
- Tachycardia
Key clinical trials
- A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (PHASE3)
- Infrasensor for Early Detection of a High-grade Obstructive NSTE-ACS
- Living WELL: A Web-Based Program for Ovarian Cancer Survivors (NA)
- SMLI With Hispanic Cancer Survivors and Caregivers (NA)
- MPV as a Predictor for ACS in Patients With MASLD
- AI-Powered ECG Detecting Culprit Vessel Blood Flow Abnormality in ACS
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) (NA)
- FORWARD CAD IDE Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |